This combination therapy resulted in tumor erythema and swelling, a transitory rise in IL-12 levels, and sustained increases in IFN-γ and thrombospondin-1, accompanied by an uninterrupted reduction in vascular endothelial growth factor (VEGF). This evidence concerns the gene VEGFA and neoplasm.